Drug intelligence / Profile preview

CB-NK

Development stage: Preclinical
Lead developer: Celularity
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies

Overview

CB-NK is an off-the-shelf allogeneic natural killer (NK) cell therapy developed by Celularity, Inc. It is a type of CAR-NK cell therapy, meaning the natural killer cells are engineered with a chimeric antigen receptor (CAR) to enhance their targeting capabilities. Celularity utilizes MaxCyte's electroporation platform for the non-viral gene editing and large-scale manufacturing of CB-NK. The drug candidate is currently in early clinical stages for the treatment of cancer, inflammatory, and regenerative indications.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CB-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB-NK.

Explore the full profile